Invesco Biotechnology & Genome ETF
PBE
103 hedge funds and large institutions have $77.6M invested in Invesco Biotechnology & Genome ETF in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 28 reducing their positions, and 3 closing their positions.
633% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 3
20% more capital invested
Capital invested by funds: $64.6M → $77.6M (+$13M)
20% more funds holding
Funds holding: 86 → 103 (+17)
2.27% more ownership
Funds ownership: 28.61% → 30.89% (+2.3%)
50% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.77M |
| 2 |
Morgan Stanley
New York
|
+$1.64M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.08M |
| 4 |
Goldman Sachs
New York
|
+$471K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$348K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
-$396K |
| 2 |
WWM
Western Wealth Management
Golden,
Colorado
|
-$258K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$150K |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$136K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$104K |
PBE Hedge Fund Activity: Q4 2022 in Review
103 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2022, worth a combined $77.6M — up 20% from $64.6M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PBE positions and 3 closed out — a net gain of 19 holders — while 14 added to existing stakes and 28 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $1.77M. The largest seller was CreativeOne Wealth, cutting an estimated $396K.
- 103 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2022, up from 86 in Q3 2022.
- Funds reported $77.6M of Invesco Biotechnology & Genome ETF stock for Q4 2022, up 20% quarter-over-quarter.
- 22 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2022 and 3 closed out, a net change of +19 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2022 was JP Morgan Chase, an estimated $1.77M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2022 was CreativeOne Wealth, an estimated $396K sold.
Based on aggregated 13F filings for Q4 2022.